The signs of [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer) include a lump in the breast, nipple discharge, a tingling, an abnormally firm or mobile breast, pain in the bone of the breast, and a lump in the armpit. Although these symptoms can appear without breast cancer, they are often present for other reasons and are usually not specific to the disease. If a lump persists after six months of an otherwise benign breast infection, it is cause for concern. The more worrisome signs arise after the lump has become larger and painful, and when changes are seen in part of the lymph nodes on the side of the infirm, such as a swollen, erythematous, or edematous lymph node.
The study concluded that the data suggests there is an opportunity for eliminating breast cancer, but further research is needed before any action can be undertaken. Results from a recent clinical trial of this study are encouraging, but we need more sophisticated technology in order to implement the method.
The most common breast cancer treatment is surgery, which is typically used in combination with chemotherapy and/or hormone therapy. Other treatments may include tamoxifen and taxane chemotherapy. Treatment options vary by tumor subtype. Patients who have luminal A breast cancer are more likely to benefit from neoadjuvant chemotherapy as adjuvant chemotherapy should be given after lumpectomy. Patients who have triple-negative breast cancer are more likely to receive mastectomy surgery and adjuvant chemotherapy. Clinicians should consider the treatment options required for their patient and/or treatment plan.
Approximately 90% of all [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer) cases arise from one of two mammary morphologic subtypes. The vast majority of invasive cancers have lost their expression of estrogen receptor. This loss appears to be independent of age, sex, age at menopause or radiation exposure. Although the mechanisms of progression are still unknown, the hormone hypothesis of carcinogenesis suggests the possible roles of estrogens and progesterone as key components of breast cancer pathogenesis.
About 100,000 women get [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer) in the United States to each year. It is the most common cancer in women in the United States.
The 5-year interval from diagnosis to distant metastasis is one of the best and most useful predictors of disease progression after breast cancer treatment by mastectomy. Because distant metastasis is the most common cause of breast cancer-related death, careful follow-up should be performed.
It is known that radiation plays an important role in the development of [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer) and it is also an important cause of secondary cancers. There are many hypotheses that try to explain the relationship between the exposure to radiation and the primary causes of breast cancer, but there is not sufficient evidence to help us pinpoint the main cause of the disease.
The data do not show improved disease free survival in this patient population after a conservative treatment scheme using a high grade, but intermediate dose BBI (30 Gy), compared to a placebo of 30 Gy.
In the United States, the current average age at diagnosis is 49.4 years, although it is higher in more developed settings. This data has been previously used to determine the age of diagnosis for [metastatic [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer)](https://www.withpower.com/clinical-trials/metastatic-breast-cancer). As the cancer tends to be more aggressive as it progresses, treatment tends to be more aggressive as well, so people who get breast cancer at a young age have a higher rate of dying from the disease than when it is diagnosed at a mid-age.